Table of Contents
Thrombosis
Volume 2013, Article ID 973710, 11 pages
http://dx.doi.org/10.1155/2013/973710
Review Article

New Oral Anticoagulants in the Treatment of Pulmonary Embolism: Efficacy, Bleeding Risk, and Monitoring

1Department of Pharmaceutical Care Services, Bassett Medical Center, Cooperstown, NY 13326, USA
2Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY 14618, USA

Received 22 June 2012; Accepted 31 January 2013

Academic Editor: C. Arnold Spek

Copyright © 2013 Kelly M. Rudd and Elizabeth (Lisa) M. Phillips. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Hawkins, “Pharmacoeconomics of thrombosis management,” Pharmacotherapy, vol. 24, no. 7, part 2, pp. 95S–99S, 2004. View at Google Scholar
  2. S. M. Bates, R. Jaeschke, S. M. Stevens et al. et al., “Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest physicians evidence-based clinical practice guidelines,” Chest, vol. 141, supplement 2, pp. e351S–e418S, 2012. View at Publisher · View at Google Scholar
  3. J. Edelsberg, D. Ollendorf, and G. Oster, “Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics,” American Journal of Health-System Pharmacy, vol. 58, no. 2, pp. S4–S13, 2001. View at Google Scholar · View at Scopus
  4. E. Nutescu, “Characteristics of novel anticoagulants and potential economic implications,” American Journal of Managed Care, vol. 17, pp. S27–S32, 2011. View at Google Scholar
  5. C. Kearon, “Natural history of venous thromboembolism,” Circulation, vol. 107, no. 23, supplement 1, pp. I22–I30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Oake, D. A. Fergusson, A. J. Forster, and C. Van Walraven, “Frequency of adverse events in patients with poor anticoagulation: a meta-analysis,” Canadian Medical Association Journal, vol. 176, no. 11, pp. 1589–1594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Rose, A. Ozonoff, R. W. Grant, L. E. Henault, and E. M. Hylek, “Epidemiology of subtherapeutic anticoagulation in the United States,” Circulation: Cardiovascular Quality and Outcomes, vol. 2, no. 6, pp. 591–597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Hamby, W. B. Weeks, and C. Malikowski, “Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic,” Effective Clinical Practice, vol. 3, no. 4, pp. 179–184, 2000. View at Google Scholar
  9. A. M. Holbrook, J. A. Pereira, R. Labiris et al., “Systematic overview of warfarin and its drug and food interactions,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1095–1106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Murin, P. S. Romano, and R. H. White, “Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism,” Thrombosis and Haemostasis, vol. 88, no. 3, pp. 407–414, 2002. View at Google Scholar · View at Scopus
  11. R. Bauersachs, S. D. Berkowitz, B. Brenner et al. et al., “Oral rivaroxaban for symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 363, no. 26, pp. 2499–2510, 2010. View at Google Scholar
  12. H. R. Buller, A. W. A. Lensing, M. H. Prins et al., “A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein DVT dose-ranging study,” Blood, vol. 112, no. 6, pp. 2242–2247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. “Secondary Prevention of Venous Thrombo Embolism (VTE),” NCT00329238, 2012, http://www.clinicaltrials.gov/ct2/show/NCT00329238?term=NCT00329238&rank=1.
  14. S. Schulman, C. Kearon, A. K. Kakkar et al., “Dabigatran versus warfarin in the treatment of acute venous thromboembolism,” The New England Journal of Medicine, vol. 361, no. 24, pp. 2342–2352, 2009. View at Google Scholar
  15. Elise S. Eerenberg, Pieter W. Kamphuisen, Meertien K. Sijpkens, Joost C. Meijers, Harry R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Google Scholar
  16. J. van Ryn, J. van Ryn, M. Kink-Eiband, and A. Clemens, “The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation,” in Proceedings of the 53rd American Society of Hematology Annual Meeting, San Diego, Calif, USA, December 2011, Poster abstract 2216.
  17. G. William and R. Aaron, “Reversing dabigatran with feiba in a patient with a transseptal perforation during cardiac ablation,” Critical Care Medicine, vol. 39, no. 12, p. 243, 2011. View at Publisher · View at Google Scholar
  18. Pradaxa (Dabigatran) Package Insert, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn, USA, 2012.
  19. S. Schulman and M. A. Crowther, “How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch,” Blood, vol. 119, no. 13, pp. 3016–3023, 2012. View at Google Scholar
  20. M. Levi, J. H. Levy, H. F. Andersen, and D. Truloff, “Safety of recombinant activated factor VII in randomized clinical trials,” New England Journal of Medicine, vol. 363, no. 19, pp. 1791–1800, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Xarelto (Rivaroxaban) Package Insert, Janssen Pharmaceuticals, Titusville, NJ, USA, 2011.
  22. J. van Ryn, D. Ruehl, H. Priepke, N. Hauel, and W. Wienen, “Reversibility of the anticoagulant effect of high doses of dabigatran by rFVIIa or PCC,” in Proceedings of the 13th Congress of the European Hematology Association, June 2008.
  23. N. Raghavan, C. E. Frost, Z. Yu et al., “Apixaban metabolism and pharmacokinetics after oral administration to humans,” Drug Metabolism and Disposition, vol. 37, no. 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. B. I. Eriksson, D. J. Quinlan, and J. I. Weitz, “Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development,” Clinical Pharmacokinetics, vol. 48, no. 1, pp. 1–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Stangier, “Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate,” Clinical Pharmacokinetics, vol. 47, no. 5, pp. 285–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Coumadin (Wafarin) Package Insert, Bristol Meyers Squibb Company, Princeton, NJ, USA, 2010.
  27. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. L. Crackowski, and G. Pernod, “Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers,” Thrombosis and Haemostasis, vol. 108, no. 2, pp. 217–224, 2012. View at Google Scholar
  28. W. Zhou, S. Schwarting, S. Illanes et al., “Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran,” Stroke, vol. 42, no. 12, pp. 3594–3599, 2011. View at Google Scholar
  29. T. E. Warkentin, P. Margetts, S. J. Connolly, A. Lamy, C. Ricci, and J. W. Eikelboom, “Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding,” Blood, vol. 119, no. 9, pp. 2172–2174, 2012. View at Google Scholar
  30. H. J. Kolde, “Determining the exact concentration of direct thrombin inhibitors (DTI) in plasma,” 2012, http://www.cli-online.com/featured-articles/determining-the-exact-concentration-of-direct-thrombin-inhibitors-dti-in-plasma/index.html.
  31. Eliquis (Apixaban) Prescribing Information, Bristol Meyers Squibb Company, Princeton, NJ, USA, 2012.
  32. L. Wang, D. Zhang, N. Raghavan et al., “In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome p450 phenotyping, inhibition, and induction studies,” Drug Metabolism and Disposition, vol. 38, no. 3, pp. 448–458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. “Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism,” 2012, http://www.clinicaltrials.gov/ct2/show/NCT00643201?term=NCT00643201&rank=1.
  34. G. Agnelli, H. R. Buller, A. Cohen et al., “Apixaban for extended treatment of venous thromboembolism,” The New England Journal of Medicine, 2012. View at Publisher · View at Google Scholar
  35. S. Schulman, A. K. Kakkar, S. M. Schellong et al., “A Randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II),” in Proceedings of the 53rd ASH Annual Meeting and Exposition, San Diego, Calif, USA, December 2011.
  36. “Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE,” 2012, http://www.clinicaltrials.gov/ct2/show/NCT00558259?term=NCT00558259&rank=1.
  37. “Pradaxa (dabigatran etexilate mesylate): Drug Safety Communication—Safety Review of Post-Market Reports of Serious Bleeding Events,” 2012, http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm.
  38. “Quarter Watch 2011 Annual Report,” Instiute for Safe Medication Practices.
  39. H. R. Buller, M. H. Prins, A. W. Lensin et al. et al., “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism,” The New England Journal of Medicine, vol. 366, no. 14, pp. 1287–1297, 2012. View at Publisher · View at Google Scholar
  40. E. Romualdi, M. P. Donadini, and W. Ageno, “Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study),” Expert Review of Cardiovascular Therapy, vol. 9, no. 7, pp. 841–844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. K. M. Rudd and J. G. Dier, “Comparison of two different models of anticoagulation management services with usual medical care,” Pharmacotherapy, vol. 30, no. 4, pp. 330–338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. M. Garabedian-Ruffalo, D. R. Gray, M. J. Sax, and R. L. Ruffalo, “Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic,” American Journal of Hospital Pharmacy, vol. 42, no. 2, pp. 304–308, 1985. View at Google Scholar · View at Scopus
  43. S. J. A. Wilson, P. S. Wells, M. J. Kovacs et al., “Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial,” Canadian Medical Association Journal, vol. 169, no. 4, pp. 293–298, 2003. View at Google Scholar · View at Scopus
  44. J. E. Lafata, S. A. Martin, S. Kaatz, and R. E. Ward, “Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis,” Journal of Thrombosis and Thrombolysis, vol. 9, supplement 1, pp. S13–S19, 2000. View at Google Scholar · View at Scopus
  45. A. G. Staresinic, C. A. Sorkness, B. M. Goodman, and D. W. Pigarelli, “Comparison of outcomes using 2 delivery models of anticoagulation care,” Archives of Internal Medicine, vol. 166, no. 9, pp. 997–1006, 2006. View at Google Scholar · View at Scopus